5-溴-2-氯-4-氟苯甲酸甲酯 | 1502717-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-氯-4-氟苯甲酸甲酯
• 英文名称: Methyl 5-bromo-2-chloro-4-fluorobenzoate
• CAS: 1502717-31-8
• 化学式: C₈H₅BrClFO₂
• 分子量: 267.48
• InChiKey: JRAHMMKAIQOCDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H331
• 包装等级：
  III

文献信息

• [EN] TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLOPYRIDINYLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2022086828A1

  公开（公告）日：2022-04-28

  Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,Formula (I): are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

  具有公式（I）的化合物，其对映异构体、顺反异构体、立体异构体、药学上可接受的盐，公式（I）如下：可用作激酶调节剂，包括RIPK1调节剂。所有变量均如本文所定义。
• Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
  申请人：Ardelyx, Inc.

  公开号：US10392413B2

  公开（公告）日：2019-08-27

  The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

  本发明涉及可用于治疗化疗引起的腹泻、糖尿病、II 型糖尿病、妊娠糖尿病、空腹血糖受损、糖耐量受损、胰岛素抵抗、高血糖、肥胖、代谢综合征、溃疡性结肠炎、克罗恩病、肠外营养相关疾病，尤其是短肠综合征和肠易激综合征（IBS），以及其他与 TGR5 相关的疾病和失调的非系统性 TGR5 激动剂，其配方如下： 其中 R1、R2、R2′、R3、R4、X1、X2、X3、X4、Q 和 n 如本文所述。
• SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS
  申请人：Ardelyx, Inc.

  公开号：EP3390382A1

  公开（公告）日：2018-10-24
• TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20220119388A1

  公开（公告）日：2022-04-21

  Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
• [EN] SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] UTILISATION DE COMPOSÉS 4-PHÉNYL PYRIDINE SUBSTITUÉS EN TANT QU'AGONISTES NON SYSTÉMIQUES DU TGR5
  申请人：ARDELYX INC

  公开号：WO2017106818A1

  公开（公告）日：2017-06-22

  The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: (I'), where R1, R2, R2', R3, R4, X1, X2, X3, X4, Q, and n are described herein.